Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?

[Image: see text] We analyzed therapeutic areas most commonly targeted by academia since 2001, finding a domination of certain oncology and infectious diseases. These findings raise important questions about whether this trend reflects an expanded opportunity arising from academic research or a trou...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinch, Michael S., Horn, Caitlin, Kraft, Zachary, Schwartz, Tyler
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552459/
https://www.ncbi.nlm.nih.gov/pubmed/34723140
http://dx.doi.org/10.1021/acsptsci.0c00167
_version_ 1784591379344654336
author Kinch, Michael S.
Horn, Caitlin
Kraft, Zachary
Schwartz, Tyler
author_facet Kinch, Michael S.
Horn, Caitlin
Kraft, Zachary
Schwartz, Tyler
author_sort Kinch, Michael S.
collection PubMed
description [Image: see text] We analyzed therapeutic areas most commonly targeted by academia since 2001, finding a domination of certain oncology and infectious diseases. These findings raise important questions about whether this trend reflects an expanded opportunity arising from academic research or a troubling sign of an industry struggling with the challenges of innovation.
format Online
Article
Text
id pubmed-8552459
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-85524592021-10-29 Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma? Kinch, Michael S. Horn, Caitlin Kraft, Zachary Schwartz, Tyler ACS Pharmacol Transl Sci [Image: see text] We analyzed therapeutic areas most commonly targeted by academia since 2001, finding a domination of certain oncology and infectious diseases. These findings raise important questions about whether this trend reflects an expanded opportunity arising from academic research or a troubling sign of an industry struggling with the challenges of innovation. American Chemical Society 2020-10-28 /pmc/articles/PMC8552459/ /pubmed/34723140 http://dx.doi.org/10.1021/acsptsci.0c00167 Text en © 2020 American Chemical Society https://pubs.acs.org/page/policy/authorchoice_termsofuse.htmlThis is an open access article published under an ACS AuthorChoice License (https://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Kinch, Michael S.
Horn, Caitlin
Kraft, Zachary
Schwartz, Tyler
Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?
title Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?
title_full Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?
title_fullStr Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?
title_full_unstemmed Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?
title_short Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?
title_sort rising academic contributions to drug development: evidence of vigor or trauma?
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552459/
https://www.ncbi.nlm.nih.gov/pubmed/34723140
http://dx.doi.org/10.1021/acsptsci.0c00167
work_keys_str_mv AT kinchmichaels risingacademiccontributionstodrugdevelopmentevidenceofvigorortrauma
AT horncaitlin risingacademiccontributionstodrugdevelopmentevidenceofvigorortrauma
AT kraftzachary risingacademiccontributionstodrugdevelopmentevidenceofvigorortrauma
AT schwartztyler risingacademiccontributionstodrugdevelopmentevidenceofvigorortrauma

Ejemplares similares